BMS 986171

Drug Profile

BMS 986171

Alternative Names: BMS986171

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antifibrotics; Fibroblast growth factors; Hepatoprotectants
  • Mechanism of Action Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatic fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

  • 11 Apr 2018 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis presented at the The International Liver Congress (ILC-2018)
  • 11 Nov 2016 Adverse events and pharmacokinetics data from a phase I trial in Healthy subjects presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 05 Nov 2016 Bristol-Myers Squibb completes a phase-I clinical trial in Hepatic fibrosis and Non-alcoholic steatohepatitis (In volunteers) in USA (SC) (NCT02538874)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top